NMRA Stock Forecast: Neumora Therapeutics, Inc. Price Predictions for 2026-2027

Last close, 20 Nov 2026
$0.33
−3.78% on the day

The median 12-month analyst price target for Neumora Therapeutics, Inc. is $5. Ticker Nerd's systematic factor model, run across ~4,300 US stocks, ranks it 35 of 100 as at 21 Nov 2026 — in the lower half.

Market cap
$65.5M
Ticker Nerd rank
35/ 100
Median analyst target
$5.00
Analysts covering
8
Revenue$0.0
Operating income−$42.2M
Net income−$43.1M
Free cash flow−$39.5M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−22.2%
1M
−28.2%
YTD
−81.3%
1Y
−85.9%
From 52W high
−90.7%
From 52W low
0.0%
$0.33
$3.59
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

One number for the whole business

Consensus tells you what everyone already believes. The model scores Neumora Therapeutics, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 21 Nov 2026
35/ 100

Percentile across ~4,300 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Growth
82
Accruals
79
Revisions
61
Volatility
31
Value
24
Quality
17
Momentum
15
Issuance
10

Growth (82): Sales and profits are climbing, and climbing faster than before.

Issuance (10): The company has been issuing shares or taking on financing, diluting existing holders.

Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.

Wall Street

NMRA stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on NMRA, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$0.00$2.00$4.00$6.00$8.00Jan 26Apr 26Jul 26Oct 26NMRAHigh $8.00Median $5.00Low $3.00

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says8 analysts
7
Buy
0
Hold
1
Sell
$3.00
Low
$5.00
Median
$8.00
High
Recent analyst actionsNewest first
DateFirmActionRatingTarget
13 July 2026RBC CapitalMaintainsOutperform$7.00 → $5.00
18 June 2026MizuhoMaintainsOutperform—
16 June 2026HC Wainwright & Co.MaintainsBuy—
16 June 2026NeedhamMaintainsBuy—
31 Mar 2026GuggenheimReiteratesBuy—
31 Mar 2026NeedhamReiteratesBuy—
17 Feb 2026William BlairUpgradeOutperform—
12 Jan 2026Leerink PartnersInitiatesOutperform—
1 Dec 2025RBC CapitalUpgradeOutperform—
17 Nov 2025StifelMaintainsHold—
28 Oct 2025NeedhamMaintainsBuy—
27 Oct 2025GuggenheimUpgradeBuy—
16 Sept 2025JP MorganDowngradeUnderweight—
16 July 2025MizuhoMaintainsOutperform—
13 May 2025NeedhamReiteratesBuy—
10 Apr 2025NeedhamReiteratesBuy—
2 Apr 2025B of A SecuritiesDowngradeUnderperform—
10 Mar 2025GuggenheimDowngradeNeutral—
7 Mar 2025HC Wainwright & Co.ReiteratesBuy—
7 Mar 2025StifelDowngradeHold—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Wall Street targets run 12 to 18 months out. No analyst publishes a 2030 price target for NMRA.

Market Radar

This page is one stock. Monday covers all of them.

NMRA appears in the Radar on the weeks it earns a place.

  • Market Radar, every Monday: the week's biggest rank moves across ~4,300 US stocks, and the reason for each.
  • The AI build-out map, free: every AI company we track on one page, with the model's Top picks in all four parts.

Free. Unsubscribe any time. Privacy

The AI build-out map
PDF
  • AI cloud capacity

    MSFTAMZNGOOGLORCL

  • AI chips

    NVDAAVGOAMDMU

  • AI networking and servers

    ANETDELLLITECRDO

  • Data centre power

    VRTCEGGEVVST

Performance

NMRA vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 20 Nov 2026, Neumora Therapeutics, Inc. returned −85.9% against +6.9% for the S&P 500, dividends included.

NMRA vs S&P 500, last 12 monthsTotal return, rebased to 100
050100150Jan 26Apr 26Jul 26Oct 26NMRAS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

NMRA analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingThis fiscal year
Analysts raising
1
Analysts cutting
0
Fundamentals

Financials

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
—
Price / sales
—
Price / book
3.3×

Cheaper than 28% of US stocks

EV / EBITDA
—
Growth & margins
Revenue growth (YoY)
—
Earnings growth (YoY)
—
Gross margin
—
Operating margin
—
Net margin
—
Returns & dividend
Return on equity
−252.7%

Higher than 6% of US stocks

Return on assets
−85.6%

Higher than 4% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,300 US stocks Ticker Nerd covers, among those reporting the figure.

Statistics

Key statistics

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Neumora Therapeutics, Inc. has a market value of $65.5M and an enterprise value of $33.4M.

  • Revenue in the twelve months to 30 June 2026: $0.0.

  • Net income over the same four quarters: −$212.7M.

  • Diluted earnings per share, trailing twelve months: −$1.23.

  • Free cash flow in the twelve months to 30 June 2026: −$180.5M.

  • Shares outstanding: 185.3M.

  • Neumora Therapeutics, Inc. employs 60 people.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 20 Nov 2026

Data provided by Twelve Data

Peers

NMRA and its peers

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
NMRANeumora Therapeutics, Inc.$65.5M35
VTVTvTv Therapeutics, Inc.$61.1M69
CSBRChampions Oncology, Inc.$59.8M27
NTRBNutriband, Inc.$59.8M33
FBIOFortress Biotech, Inc.$63.1M87
NRXSNeurAxis, Inc.$58.3M47
ATRAAtara Biotherapeutics, Inc.$63.5M74

Take a look at NMRA’s peer groups, ranked by the model: healthcare stocks · biotech stocks.

Look up any of the roughly 4,300 stocks we score.

The rank is the raw material. Whether the rules would actually own Neumora Therapeutics, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

FAQ

Questions about NMRA

What is the NMRA stock price forecast for 2026-2027?

The median 12-month analyst price target for Neumora Therapeutics, Inc. is $5, with estimates ranging from $3 to $8. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is NMRA stock a buy right now?

Of the 8 analysts covering Neumora Therapeutics, Inc., 7 rate it a Buy, 0 a Hold and 1 a Sell. Ticker Nerd's systematic factor model ranks Neumora Therapeutics, Inc. 35 out of 100 across roughly 4,300 US stocks as at 21 Nov 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank NMRA?

As at 21 Nov 2026, Neumora Therapeutics, Inc. ranks 35 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,300 US stocks, built from its factor families. Its strongest factor family is Growth (82 of 100).

Will NMRA stock go up?

No one can know that. What the data says: the median 12-month target from 8 analysts is $5, and Ticker Nerd's factor model ranks Neumora Therapeutics, Inc. 35 out of 100 as at 21 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the NMRA stock forecast for 2030?

No analyst covering Neumora Therapeutics, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for NMRA are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $3 to $8 over the next 12 months.

How has NMRA stock performed over the past year?

Neumora Therapeutics, Inc. returned -85.9% over the 12 months to 20 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Neumora Therapeutics, Inc. do?

Neumora Therapeutics, Inc. Common Stock represents Neumora Therapeutics, a clinical-stage biopharmaceutical company focused on developing treatments for brain diseases, neuropsychiatric disorders, and neurodegenerative conditions. The company applies a precision medicine approach that combines neuroscience, biological insight, and data science to identify and advance therapies aimed at central nervous system targets.

Company

About Neumora Therapeutics, Inc.

Neumora Therapeutics, Inc. Common Stock represents Neumora Therapeutics, a clinical-stage biopharmaceutical company focused on developing treatments for brain diseases, neuropsychiatric disorders, and neurodegenerative conditions. The company applies a precision medicine approach that combines neuroscience, biological insight, and data science to identify and advance therapies aimed at central nervous system targets. Its current pipeline includes candidate medicines in clinical and preclinical development for major depressive disorder, agitation associated with dementia, schizophrenia, Parkinson’s disease, ALS, and obesity-related metabolic disease. Neumora Therapeutics is positioned within the biotechnology sector as a research-driven company centered on novel mechanisms of action for underserved neurological and psychiatric disorders. The common stock reflects the market’s view of a company whose value is tied to progress across this specialized drug development pipeline and the broader demand for new CNS therapies.

CEO Dr. Joshua Pinto Ph.D. · 60 employees · United States · https://www.neumoratx.com